Scientists have revealed neuronal mechanisms underlying the formation and retrieval of cocaine use-associated memories. Their research sheds light on how drug addiction develops and reveals pathways that can be exploited for the development of strategies to treat cocaine addiction. The environmental context in which addicts experience the rewarding effects of cocaine can readily elicit cocaine-associated […]
Home »
Fast-acting psychedelic associated with improvements in depression/anxiety
Johns Hopkins researchers have discovered that use of the synthetic psychedelic 5-methocy-N,-N-dimethyltryptamine (5-MeO-DMT) appears to be associated with unintended improvements in self-reported depression and anxiety when given in a ceremonial group setting. 5-MeO-DMT is a psychedelic that is found in the venom of Bufo Alvarius toads, in a variety of plants species, and can be […]
Drug use, religion explain ‘reverse gender gap’ on marijuana
Women tend to be more conservative than men on political questions related to marijuana. A recent study finds that this gender gap appears to be driven by religion and the fact that men are more likely to have used marijuana. “This subject got our attention because it is the rare political issue where women are […]
Cognitive changes in offspring of heavy cannabis-using rats: Cannabis use is common among pregnant women, but effects are rarely tested
Washington State University researchers have seen cognitive changes in the offspring of rats exposed to heavy amounts of cannabis. Their work is one of the rare studies to look at the effects of cannabis during pregnancy. The drug is the most commonly used illicit substance among pregnant women. Ryan McLaughlin, an assistant professor of Integrative […]
Effective ketamine doses for treatment-resistant depression
A study led by Massachusetts General Hospital (MGH) investigators identifies two subanesthetic dosage levels of the anesthetic drug ketamine that appear to provide significant symptom relief to patients with treatment-resistant depression. In the October 2018 issue of Molecular Psychiatry they describe finding that single intravenous doses of 0.5 mg/kg and 1.0 mg/kg were more effective […]
Reclassification recommendations for drug in ‘magic mushrooms’: If phase III clinical trials are successful, researchers suggest categorizing the drug as schedule IV
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug — one with no known medical potential — to a schedule IV drug such as prescription sleep aids, but […]
Nerve pain in the legs? Medical marijuana may alter brain connections, bring relief
When medical marijuana is taken for chronic nerve pain, it may provide pain relief by reducing connections between the areas of the brain that process emotions and sensory signals, according to a study published in the September 5, 2018, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study looked […]